TAE Life Sciences

TAE Life Sciences is a privately held biotechnology company developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT) for treating cancer. The company is the only one working on developing both next-generation targeted boron drugs and a low-energy accelerator-based neutron system optimized for an in-hospital BNCT program. Their proprietary boronated drug BTS is designed to selectively accumulate in tumor cells, and when irradiated with the low-energy neutron beam from their Alphabeam system, it delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers.

In addition to BTS, TAE Life Sciences has also developed Fc-engineered antibodies for site-specific conjugation and reduced effector function, enabling precise targeting for both Antibody Boron Conjugates (ABC) for BNCT and Antibody Drug Conjugates (ADC). In March 2024, the company was granted a US patent covering the compositions of their boronated amino acid compounds BTS and BTS(OMe), along with novel methods for their production.

TAE Life Sciences' Alphabeam BNCT system and targeted boron drugs are currently in the investigational stage. In February 2023, the first accelerator-based BNCT clinical research center at Xiamen Humanity Hospital in China, utilizing TAE Life Sciences' neutron beam system, treated 12 patients with recurrent cancers as part of an investigator-initiated trial, marking the first human patients treated with this technology outside of Japan.

Key customers and partnerships

In June 2024, TAE Life Sciences announced a strategic distribution partnership with Radiosurgery Global (RSG) for India. RSG excels in providing comprehensive support through a network of skilled consultants, partners, and advisors specializing in sales channels, project management, construction, marketing, engineering, service, and financing, which will help TAE Life Sciences strategically target radiation oncology professionals and institutions adopting the latest cancer care innovations in India.

In January 2023, TAE Life Sciences partnered with AIVITA Biomedical to address unmet needs in glioblastoma treatment. AIVITA will provide tumor-initiating cells isolated and expanded from glioblastoma tumors to be used by TAE Life Sciences for therapeutic target identification and development of novel boron target drugs for future BNCT treatments.